Skip to Main Content
Phase I

MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research

  • Study HIC#:1304011902
  • Last Updated:07/15/2021

We hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. the Artemis system will be used to collect one extra research biopsy from each ROI. An average of 2 ROIs are identified for each case; therefore an average of 2 additional biopsies would be required for this research study. These research biopsies will not affect prostate biopsies collected as part of standard clinical care.

  • Age18 years - 80 years
  • GenderMale only
  • Start Date06/24/2013
  • End Date10/31/2023

Trial Purpose and Description

The investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. These profiles will in turn enable better predictions of the malignant progression of prostate cancers in the settings of current clinical practice.

Eligibility Criteria

Inclusion Criteria:

  • Only subjects that have scheduled Artemis prostate biopsy with defined regions of interest will be included in this study

Exclusion Criteria:

  • Any subjects that are unable to provide informed consent will be excluded

Sub-Investigators

For more information about this study, contact:

Or contact the Help us Discover team on: